Analysis on Role of mTORC1/4E-BP1 Axis in Idiopathic Pulmonary Fibrosis and Research Progress of Bupleuri Radix on Its Intervention
10.13422/j.cnki.syfjx.20210803
- VernacularTitle:特发性肺纤维化中mTORC1/4E-BP1轴的作用探讨及柴胡对其干预的研究进展
- Author:
Xiao SHEN
1
;
Ling-lin HE
1
;
Fu-yuan FAN
2
;
Yu-jia LIU
2
;
Hui-ping OU
1
;
Xue-fei XIAO
2
;
Da LI
2
Author Information
1. Hunan University of Chinese Medicine，Changsha 410208，China
2. The First Hospital of Hunan University of Chinese Medicine，Changsha 410007，China
- Publication Type:Research Article
- Keywords:
mammalian target of rapamycin complex 1（mTORC1）;
4E binding protein 1（4E-BP1）;
idiopathic pulmonary fibrosis;
Bupleuri Radix
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(10):239-250
- CountryChina
- Language:Chinese
-
Abstract:
Idiopathic pulmonary fibrosis （IPF） is a common， lethal interstitial lung disease characterized by airway remodeling， inflammation， alveolar destruction， and fibrosis. The mammalian target of rapamycin complex 1/4E binding protein 1 （mTORC1/4E-BP1） axis is closely related to the expression of collagen by fibroblasts， and its role in pulmonary fibrosis remains to be further elucidated. Traditional Chinese medicine （TCM） has shown promising efficacy in improving the lung function， exercise capacity， and quality of life in patients with IPF. The theory of "same treatment for different diseases" provides a TCM theoretical basis for the treatment of pulmonary fibrosis with Bupleuri Radix， while the research in western medicine has preliminarily shown that both the formulation and single herb as well as the active ingredients of Bupleuri Radix have good therapeutic effects on pulmonary fibrosis. Therefore， this review will elaborate on the role of the mTORC1/4E-BP1 axis in the pathomechanism of IPF， as well as the research results of the active components of Bupleuri Radix on the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin protein（PI3K/AKT/mTOR） pathway， so as to provide a reference for the treatment and drug development of IPF.
